Suramin
- Generic Name
- Suramin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C51H40N6O23S6
- CAS Number
- 145-63-1
- Unique Ingredient Identifier
- 6032D45BEM
- Background
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®.
- Indication
For treatment of human sleeping sickness, onchocerciasis and other diseases caused by trypanosomes and worms.
- Associated Conditions
- -
- Associated Therapies
- -
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
- First Posted Date
- 2003-10-22
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 390
- Registration Number
- NCT00002723
- Locations
- 🇺🇸
CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States
🇺🇸CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00066768
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00054028
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Suramin in Treating Patients With Recurrent Bladder Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 15
- Registration Number
- NCT00006476
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 82
- Registration Number
- NCT00006929
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00001381
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00001266
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.